---
title: "SkinBioTherapeutics (AIM:SBTX) Report and Accounts, and Provision Update"
publisher: "Share Talk"
author: "sharetalk"
published: "2022-12-23T09:15:14+00:00"
modified: "2022-12-23T09:15:14+00:00"
date: 2022-12-23
canonical: "https://www.share-talk.com/skinbiotherapeutics-aimsbtx-report-and-accounts-and-provision-update/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["Manprit Randhawa", "SBTX", "skin health", "SkinBioTherapeutics", "Stuart J . Ashman"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# SkinBioTherapeutics (AIM:SBTX) Report and Accounts, and Provision Update

**Published:** December 23, 2022
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** Manprit Randhawa, SBTX, skin health, SkinBioTherapeutics, Stuart J . Ashman
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**Annual Report and Accounts**

**Amendment to provisions and update to Operating Loss**

23 December 2022 – SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life science company focused on skin health, announces that a copy of its Annual Report and Financial Statements for the year ended 30 June 2022, is now available from the Company’s website [https://www.skinbiotherapeutics.com/investor-relations/financial-reports](https://www.skinbiotherapeutics.com/investor-relations/financial-reports). Hard copies of the 2022 Annual Report and Financial Statements have also been posted to shareholders.

During the finalisation of the FY 2022 Annual Report & Accounts, the Group became aware of an adjustment to inventories which impacts the Group’s financial results for the year ending 30th June 2022. A provision of £266k has been made to restate inventories to net realisable value, and as a result the operating loss has increased from £2,716k (as per the unaudited full year results of 15 December 2022) to £2,982k. This has no impact on the Group’s year end net cash position of £1.8 million, as announced.

-Ends-

**For more information, please contact:**

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

---

**Original URL:** https://www.share-talk.com/skinbiotherapeutics-aimsbtx-report-and-accounts-and-provision-update/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*